Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $4.82M | $268K | $44.7M | $802K | $15.0M | $0.00 |
| Revenue growth | — | -94.4% | 16580.2% | -98.2% | 1766.5% | -100.0% |
| Operating income | -$20.0M | -$45.2M | -$4.04M | -$83.9M | -$68.0M | -$70.6M |
| Operating margin | -415.8% | -16873.5% | -9.0% | -10463.1% | -454.1% | — |
| Net income | -$17.7M | -$50.9M | $5.34M | -$73.3M | -$61.1M | -$66.4M |
| Net margin | -367.3% | -18979.5% | 11.9% | -9145.5% | -408.0% | — |
| EPS (diluted) | -$2.24 | -$1.96 | $0.14 | -$1.91 | -$1.55 | -$1.64 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$11.0M | -$32.6M | -$14.4M | -$50.9M | -$28.9M | -$48.0M |
| Capital expenditures | $293K | $1.15M | $6.14M | $5.41M | $892K | $37.0K |
| Free cash flow | -$11.3M | -$33.7M | -$20.6M | -$56.3M | -$29.8M | -$48.0M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $43.3M | $214M | $194M | $142M | $111M | $70.5M |
| Total assets | $50.7M | $281M | $270M | $215M | $160M | $98.2M |
| Total liabilities | $53.8M | $28.2M | $27.0M | $27.5M | $30.2M | $23.9M |
| Shareholders' equity | -$36.9M | $252M | $243M | $187M | $130M | $74.2M |
| Retained earnings | -$57.7M | -$109M | -$103M | -$177M | -$238M | -$304M |
| Shares (wtd avg diluted) | 7.90M | 25.9M | 38.2M | 38.4M | 39.3M | 40.5M |
Every figure is extracted from Barinthus Biotherapeutics plc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.